When is repatha going generic?

When will Repatha (evolocumab) go generic?

Repatha is a biologic (an antibody), so it does not “go generic” in the traditional way small-molecule drugs do. Instead, competitors typically enter as biosimilars.

Based on available patent and exclusivity information tracked by DrugPatentWatch.com, Repatha’s key exclusivities are not expected to end until the mid-2030s in the U.S., meaning biosimilar launch is not expected before then. [1]

What does “generic Repatha” mean for patients and prescribers?

For biologics like Repatha, the closest equivalent to a generic is a biosimilar approved by regulators. Biosimilars can be substituted only under the rules that apply in each country/state and for each specific product label.

So, when people ask when Repatha will “go generic,” they’re usually asking when biosimilars will be able to launch and be approved for sale.

What determines the timing: patents, exclusivity, or both?

Both can matter:
- Patent barriers can block other manufacturers from launching an approved biosimilar product.
- Data and marketing exclusivity can also delay approval or commercial launch even if some patents expire earlier.

DrugPatentWatch.com consolidates this type of information into predicted timelines for when exclusivity/patents are expected to clear. [1]

Where can I check the exact predicted date?

DrugPatentWatch.com has a live page for Repatha that shows the key patent/exclusivity timeline it uses for “when generic/biosimilar could enter.” [1]

Sources:
[1] https://www.drugpatentwatch.com/